Pantop%2525252525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. It is available in oral (delayed-release tablets, suspension) and intravenous (IV) formulations. ## Primary Indications * Erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions, including Zollinger-Ellison syndrome. * Short-term treatment of GERD symptoms (off-label). * Stress ulcer prophylaxis in critically ill patients (off-label). ## Adult Dosing * **Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg orally once daily. * **Hypersecretory Conditions:** Starting dose 40 mg twice daily. Doses up to 240 mg/day have been used; individualize based on patient needs. * **Stress Ulcer Prophylaxis (Off-label):** 40 mg IV once daily or every 12 hours. ## Pediatric Dosing * **GERD (5 years and older):** * 15 kg to < 40 kg: 20 mg once daily. * ≥ 40 kg: 40 mg once daily. * Duration: Up to 8 weeks. * **Note:** Dosing for infants and children < 5 years is typically determined by specialized pediatric protocols, as safety and efficacy data are limited. ## Dose Adjustments * **Hepatic Impairment:** No initial dose adjustment required; however, use caution and monitor LFTs in severe impairment. Limited data suggest a maximum of 20 mg/day may be appropriate in severe liver disease. * **Renal Impairment:** No dosage adjustment necessary. * **Geriatric:** No dosage adjustment necessary. ## Contraindications * Hypersensitivity to pantoprazole or any component of the formulation. * Concurrent use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, injection site reactions (IV). * **Serious:** *Clostridioides difficile*-associated diarrhea, acute interstitial nephritis, vitamin B12 deficiency (long-term use), hypomagnesemia, bone fractures (long-term, high-dose use), and cutaneous/systemic lupus erythematosus. ## Key Drug Interactions * **pH-Dependent Absorption:** May decrease absorption of drugs like atazanavir, ketoconazole, and iron salts. * **CYP2C19/3A4:** Pantoprazole is primarily metabolized by CYP2C19; use caution if combined with potent inhibitors/inducers, though clinical significance is generally low. * **Methotrexate:** High-dose PPI use may increase serum methotrexate levels; monitor closely. * **Clopidogrel:** Interaction significance is controversial, but current guidelines suggest no need to alter therapy. ## Monitoring * Monitor for symptomatic relief of GERD. * In long-term therapy, monitor for signs of B12 deficiency and hypomagnesemia. * Monitor for refractory diarrhea, which may indicate *C. difficile*. ## Clinical Pearls * **Administration:** Oral delayed-release tablets should be swallowed whole; do not crush or chew. IV administration should be a slow injection (at least 2 minutes) or a short-term infusion. * **Tapering:** Long-term PPI use may cause rebound acid hypersecretion upon discontinuation; consider a gradual taper for patients on long-term therapy. * **Efficacy:** Pantoprazole is pharmacokinetically equivalent to other PPIs; however, it has a favorable profile regarding drug-drug interactions compared to omeprazole. *** **Educational Disclaimer:** This information is for educational purposes only. Always verify doses, contraindications, and drug interactions with current, institution-specific prescribing information or a reliable clinical database before administering medication.